tiprankstipranks
Advertisement
Advertisement
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
PremiumCompany AnnouncementsInflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
28d ago
InflaRx presents vilobelimab data
Premium
The Fly
InflaRx presents vilobelimab data
1M ago
InflaRx price target lowered to $14 from $22 at Guggenheim
Premium
The Fly
InflaRx price target lowered to $14 from $22 at Guggenheim
1M ago
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
PremiumRatingsInflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
4M ago
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%
Premium
The Fly
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%
4M ago
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
Premium
Company Announcements
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
4M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
5M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
Premium
Ratings
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100